Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma

Coelho, Sabrina Mendes; Vaisman, Fernanda; Buescu, Alexandru; Mello, Renata; Carvalho, Denise P.

doi:10.1590/s0100-879x2010007500120

Cited by 13 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rats, saturated FFA have shown to increase intramuscular palmitic acid accumulation that may lead to insulin resistance (Reynoso et al, 2003). In humans, a positive association between serum FFA composition and diabetes was reported (Vessby et al, 1994; Coelho et al, 2011). …”

Section: Beta Cell Demise and Dysfunctionmentioning

confidence: 97%

Beta Cell Dysfunction and Insulin Resistance

Cerf¹

2013

Front. Endocrinol.

741

471

View full text Add to dashboard Cite

Beta cell dysfunction and insulin resistance are inherently complex with their interrelation for triggering the pathogenesis of diabetes also somewhat undefined. Both pathogenic states induce hyperglycemia and therefore increase insulin demand. Beta cell dysfunction results from inadequate glucose sensing to stimulate insulin secretion therefore elevated glucose concentrations prevail. Persistently elevated glucose concentrations above the physiological range result in the manifestation of hyperglycemia. With systemic insulin resistance, insulin signaling within glucose recipient tissues is defective therefore hyperglycemia perseveres. Beta cell dysfunction supersedes insulin resistance in inducing diabetes. Both pathological states influence each other and presumably synergistically exacerbate diabetes. Preserving beta cell function and insulin signaling in beta cells and insulin signaling in the glucose recipient tissues will maintain glucose homeostasis.

show abstract

Section: Beta Cell Demise and Dysfunctionmentioning

confidence: 97%

Beta Cell Dysfunction and Insulin Resistance

Cerf¹

2013

Front. Endocrinol.

741

471

View full text Add to dashboard Cite

show abstract

“…The studies included those utilizing WBS [5,[23][24][25][26][27][28][29][30][31], Tg [23,27,28,32], RECIST [24,27,33], or WHO criteria [34,35]. 5 studies at 2 institutions may have been duplicated [5,30,32,33,35], but were included because they were based on different response criteria. The characteristics of the 14 studies included are summarized in the supplemental table 1 (www.karger.com/?…”

Section: Study Characteristicsmentioning

confidence: 99%

Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Purpose: The purpose of this study was to evaluate the response of retinoic acid (RA) in radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Methods: Systematic searches of MEDLINE (from inception to December 2016) and of EMBASE (from inception to December 2016) were performed for English-language publications on thyroid cancer treated with RA. Studies were classified according to the response criteria used: (1) ¹²³I or ¹³¹I whole body scintigraphy (WBS), (2) serum thyroglobulin (Tg) level, (3) the response evaluation criteria in solid tumors (RECIST) version 1.0, and (4) World Health Organization (WHO) criteria. Results: Disease response rates as determined by WBS ranged widely between 6.2% and 46.1% with a pooled disease response rate of 27.6% (95% confidence interval: 21.7-34.0%). Response rates as determined by Tg level ranged from 56.6% to 83.3% (pooled response rate 61.3% (51.0-70.9%)), RECIST response rates from 0% to 45.5% (pooled response rate 17.0% (1.4-44.5%)), and according to WHO criteria, the pooled response rate was 30.8% (12.7-52.7%). Conclusions: A minority of patients with RAI-refractory DTC respond to RA treatment.

show abstract

“…64 In another study, 16 patients whose tumors no longer had RAI-uptake, as documented by post-RAI treatment scans, were treated with retinoic acid followed by RAI; 3 patients had tumor responses and another 4 patients had disease stabilization; PFS was 26.5months. 65 In addition to its affect on NIS/RAI-uptake, retinoic acid may decrease thyroid cell proliferation via another mechanism, attenuation of VEGF secretion. 66 …”

Section: 0 Other Agents With Activity In Thyroid Cancermentioning

confidence: 99%

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches

Harris

Bible

2011

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction Thyroid cancer is an emerging public health concern. In the U.S., its incidence has doubled in the past decade, making it the 8th most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. Areas covered Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. Expert opinion Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity modulated radiation therapy appears to extend survival for patients with locoregionally-confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.

show abstract

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma

Cited by 13 publications

References 28 publications

Beta Cell Dysfunction and Insulin Resistance

Beta Cell Dysfunction and Insulin Resistance

Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches

Contact Info

Product

Resources

About